Strategic partnerships Two exclusive worldwide licensing agreements with Valeant Pharmaceuticals position EyeGate as an attractive partner for distribution, manufacturing, and co-development opportunities in ocular inflammation and post-operative care.

Clinical momentum EyeGate has an active EyeGate II Delivery System with over 2,400 treatments in trials and multiple product candidates targeting ocular inflammation, pain after surgery, and uveitis, suggesting recurring opportunities for collaboration, investment, or licensing in ophthalmic therapeutics.

Productライン OBG and EGP-437 represent complementary platforms (gel-based ocular healing and iontophoretic corticosteroid delivery) with clear routes to market in post-surgical care and inflammatory eye diseases, enabling cross-sell or bundle opportunities with ophthalmology distributors.

Financial signals The company operates with low revenue (<$1M) but has active financings and warrant exercises, indicating potential appetite for strategic investments, licensing deals, or co-funding arrangements to advance clinical milestones.

Leadership continuity Recent executive movements including CEO appointment and CFO transition suggest a stable leadership focus on accelerating operations and deal-making, aligning with business development efforts to secure partnerships and monetization milestones.